Logo

Lipocine Enters into an Exclusive License Agreement with Antares to Commercialize Tlando in the US

Share this

Lipocine Enters into an Exclusive License Agreement with Antares to Commercialize Tlando in the US

Shots:

  • Lipocine to receive $11.0M up front- $5.0M as licensing fees in Jan’25 & $5.0M in Jan’26- ~$160.0M as sales-based commercial milestone based on Tlando net sales- if Antares exercises Tlando XR option & royalties on sales of Tlando
  • Antares to get an option to license Tlando XR for TRT in the US on or before March 31- 2022. Upon exercise of Tlando XR option- Lipocine to receive $4.0M as license fees- clinical & regulatory milestone of ~$35.0M along with royalties
  • Antares will lead all commercialization- post-marketing obligations & sourcing of Tlando in the US along with Tlando XR. Lipocine holds all rights for Ex-US territories & non-TRT indications for Tlando & Tlando XR

  | Ref: PR Newswire | Image: PR Newswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions